Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CES2 | O00748 | 8/20 | 0.39 |
| ▸ | CES1 | P23141 | 7/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1195001 | 0.93 | FAAH (0.41) | ALDH1A1CES2CES1FAAH | |
| SCHEMBL29064774 | 0.91 | FAAH (0.45) | ALDH1A1CES2CES1FAAH | |
| SCHEMBL6951878 | 0.91 | FAAH (0.45) | ALDH1A1CES2CES1FAAH | |
| SCHEMBL27399875 | 0.90 | FAAH (0.43) | ALDH1A1CES2CES1FAAH | |
| SCHEMBL9512475 | 0.90 | FAAH (0.43) | ALDH1A1CES2CES1FAAH | |
| Ammonia Solution, Strong SCHEMBL28884854 | 0.90 | FAAH (0.43) | ALDH1A1CES2CES1FAAH | |
| SCHEMBL18126422 | 0.88 | ALDH1A1 (0.32) | ALDH1A1LMNAHSD17B10 | |
| Ammonia Solution, Strong SCHEMBL28730804 | 0.88 | FAAH (0.42) | ALDH1A1CES2CES1FAAH | |
| SCHEMBL6180 | 0.86 | ALDH1A1 (0.36) | ALDH1A1LMNAHSD17B10 | |
| SCHEMBL18126415 | 0.86 | FAAH (0.31) | ALDH1A1CES2CES1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006002031-A1 | SUSTAINED RELEASE DOSAGE FORMS | ANDRX CORPORATION (US) | 2006-01-05 | — | — | WO | claimed |
| US-20050276849-A1 | Sustained release dosage forms | ANDRX CORPORATION | 2005-12-15 | — | — | US | claimed |
| CN-112469402-B | Orally administrable and sustained release pharmaceutical dosage forms | 拜耳公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-105101952-B | Oral sustained release formulation of tofacitinib | 辉瑞公司 | 2022-06-28 | — | — | CN | disclosed |
| US-11344519-B2 | Orally administrable modified-release pharmaceutical dosage form | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-05-31 | — | — | US | disclosed |
| US-20210283046-A1 | PHARMACEUTICAL DOSAGE FORM WHICH CAN BE ADMINISTERED ORALLY AND HAS MODIFIED RELEASE | BAYER AKTIENGESELLSCHAFT (DE) | 2021-09-16 | — | — | US | disclosed |
| US-20210113504-A1 | ORALLY ADMINISTRABLE MODIFIED-RELEASE PHARMACEUTICAL DOSAGE FORM | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-04-22 | — | — | US | disclosed |
| CN-112469402-A | Orally administrable and sustained-release pharmaceutical dosage form | 拜耳公司 | 2021-03-09 | — | — | CN | disclosed |
| US-10905667-B2 | Orally administrable modified-release pharmaceutical dosage form | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-02-02 | — | — | US | disclosed |
| US-20200237648-A1 | ORALLY ADMINISTRABLE MODIFIED-RELEASED PHARMACEUTICAL DOSAGE FORM | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-07-30 | — | — | US | disclosed |
| CN-111419817-A | Oral sustained release formulation of tofacitinib | 辉瑞公司 | 2020-07-17 | — | — | CN | disclosed |
| US-4285987-A | Process for manufacturing device with dispersion zone | ALZA CORPORATION (US) | 1981-08-25 | — | — | US | disclosed |
| US-4256108-A | Microporous-semipermeable laminated osmotic system | ALZA CORPORATION (US) | 1981-03-17 | — | — | US | disclosed |
| US-4200098-A | Osmotic system with distribution zone for dispensing beneficial agent | ALZA CORPORATION (US) | 1980-04-29 | — | — | US | disclosed |
| US-4160452-A | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina | ALZA CORPORATION (US) | 1979-07-10 | — | — | US | disclosed |
| US-4116241-A | FOR CONTROLLED ORAL ADMINISTRATION OF DRUG | ALZA CORPORATION (US) | 1978-09-26 | — | — | US | disclosed |
| US-4077407-A | POLYSACCHARIDES | ALZA CORPORATION (US) | 1978-03-07 | — | — | US | disclosed |
| US-4058122-A | Osmotic system with laminated wall formed of different materials | ALZA CORPORATION (US) | 1977-11-15 | — | — | US | disclosed |
| US-4014334-A | Laminated osmotic system for dispensing beneficial agent | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | disclosed |
| US-4008719-A | Osmotic system having laminar arrangement for programming delivery of active agent | ALZA CORPORATION (US) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200237648-A1 | ORALLY ADMINISTRABLE MODIFIED-RELEASED PHARMACEUTICAL DOSAGE FORM | GLS, ATP6V1B1, TNNC1 | ALDH1A1 1313/4885CES2 2063/4885CES1 376/4885 |
| US-10905667-B2 | Orally administrable modified-release pharmaceutical dosage form | GLS, FABP3, TNNC1 | ALDH1A1 1697/4885CES2 1428/4885CES1 420/4885 |
| US-20210113504-A1 | ORALLY ADMINISTRABLE MODIFIED-RELEASE PHARMACEUTICAL DOSAGE FORM | GLS, FABP3, TNNC1 | ALDH1A1 1697/4885CES2 1428/4885CES1 420/4885 |
| US-11344519-B2 | Orally administrable modified-release pharmaceutical dosage form | GLS, FABP3, TNNC1 | ALDH1A1 1697/4885CES2 1428/4885CES1 420/4885 |
| US-20210283046-A1 | PHARMACEUTICAL DOSAGE FORM WHICH CAN BE ADMINISTERED ORALLY AND HAS MODIFIED RELEASE | GLS, FABP3, ATP6V1B1 | ALDH1A1 826/4885CES2 2475/4885CES1 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.